Complement C1q does not bind monomeric beta-amyloid
- PMID: 8070518
- DOI: 10.1006/exnr.1994.1121
Complement C1q does not bind monomeric beta-amyloid
Abstract
The tendency of both labeled and unlabeled beta-amyloid to bind in solution to C1q, the recognition species in the complement cascade, was examined using both hydrodynamic and spectroscopic methods. Potential binding interactions were evaluated using a purified synthetic beta-amyloid 1-40 sequence, alone, and selectively labeled at the amino terminus with spectroscopic probes. The probes permitted both absorbance and fluorescence analyses of beta-amyloid binding interactions. Under conditions used for the analyses beta-amyloid exists exclusively as a monomer in solution, and C1q retains an intact quaternary structure and is capable of binding to IgM. When mixed together the monomeric beta-amyloid does not bind to, or interact with, the complement C1q at concentrations below approximately 100 microM. The data suggest that if beta-amyloid toxicity is associated with complement activation in Alzheimer's disease then monomeric beta-amyloid is likely not responsible for activation through the classical complement pathway.
Similar articles
-
Localization and cell association of C1q in Alzheimer's disease brain.Exp Neurol. 1996 Mar;138(1):22-32. doi: 10.1006/exnr.1996.0043. Exp Neurol. 1996. PMID: 8593893
-
Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation.Biochem Biophys Res Commun. 1995 Dec 26;217(3):869-75. doi: 10.1006/bbrc.1995.2852. Biochem Biophys Res Commun. 1995. PMID: 8554610
-
beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain.J Immunol. 1994 May 15;152(10):5050-9. J Immunol. 1994. PMID: 8176223
-
Native, amyloid fibrils and beta-oligomers of the C-terminal domain of human prion protein display differential activation of complement and bind C1q, factor H and C4b-binding protein directly.Mol Immunol. 2008 Jun;45(11):3213-21. doi: 10.1016/j.molimm.2008.02.023. Epub 2008 Apr 11. Mol Immunol. 2008. PMID: 18406463
-
Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q.J Neurosci Res. 1994 Nov 1;39(4):448-56. doi: 10.1002/jnr.490390412. J Neurosci Res. 1994. PMID: 7884823
Cited by
-
The significance of neuroinflammation in understanding Alzheimer's disease.J Neural Transm (Vienna). 2006 Nov;113(11):1685-95. doi: 10.1007/s00702-006-0575-6. Epub 2006 Oct 13. J Neural Transm (Vienna). 2006. PMID: 17036175 Review.
-
Contribution of Neurons and Glial Cells to Complement-Mediated Synapse Removal during Development, Aging and in Alzheimer's Disease.Mediators Inflamm. 2018 Nov 11;2018:2530414. doi: 10.1155/2018/2530414. eCollection 2018. Mediators Inflamm. 2018. PMID: 30533998 Free PMC article. Review.
-
Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice.Sci Transl Med. 2017 May 31;9(392):eaaf6295. doi: 10.1126/scitranslmed.aaf6295. Sci Transl Med. 2017. PMID: 28566429 Free PMC article.
-
Neuroinflammatory processes in Alzheimer's disease.J Neural Transm (Vienna). 2010 Aug;117(8):919-47. doi: 10.1007/s00702-010-0438-z. Epub 2010 Jul 15. J Neural Transm (Vienna). 2010. PMID: 20632195 Review.
-
Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.Clin Exp Immunol. 1999 Mar;115(3):526-33. doi: 10.1046/j.1365-2249.1999.00835.x. Clin Exp Immunol. 1999. PMID: 10193429 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources